DOCS · Doximity Inc
AI read · Neutral
The AI's read
DOCS beat revenue and raised full-year guidance, sending shares much higher after hours. The quarter showed strong prescriber growth and AI engagement gains. The market already priced a huge move — stock jumped ~66% after the print. That makes incremental upside limited and raises short-term volatility. We lean neutral on the immediate setup. Big gap moves inside a consolidating market increase whipsaw risk and favor waiting for digestion or follow-up proof of monetization.